Nevertheless, a tumor biopsy will remain the cornerstone of the work-up in metastatic breast cancer since [18F]F-FES-PET alone will not be able to inform the clinician about additional tumor biological factors such as histology and/or HER2 status. This evidence concerns the gene ERBB2 and neoplasm.